Product Information
FENOFIBRIC ACID DR 135 MG CAP is a generic product labeled by Amneal Pharmaceuticals of New York LLC, priced at $0.2863 per EA under NDC 00115132510. Its NADAC has been published 92 times since Jan 1, 2025.
FDA first approved this application on Sep 7, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the FENOFIBRIC ACID market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
135 mg/1
Manufacturer
Amneal Pharmaceuticals of New York LLCNDC
00115132510
Classification
Generic
Dosage Form
CAPSULE, DELAYED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FENOFIBRIC ACIDApproval Type
Generic (ANDA)
FDA Application
ANDA200264FDA Approved
9/7/2016
TE Code
AB
On Market Since
6/1/2024
Pharmacological Classes
Price Statistics
The NADAC for FENOFIBRIC ACID DR 135 MG CAP has been published 92 times since Jan 1, 2025, and over the history we have for it it has declined 20.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2863 per EA |
|---|---|
| All-time high | $0.3612 (Jan 15, 2025) |
| All-time low | $0.2366 (Mar 18, 2026) |
| 52-week high | $0.2947 |
| 52-week low | $0.2366 |
| Median price | $0.2796 |
| Average price | $0.2799 |
| Largest weekly change | +15.0% (Jun 18, 2025) |
| Weeks tracked | 92 |
| Tracking since | Jan 1, 2025 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Amneal Pharmaceuticals of New York LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
FENOFIBRIC ACID market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Peroxisome Proliferator Receptor alpha Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FENOFIBRIC ACID DR 135 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for FENOFIBRIC ACID DR 135 MG CAP, manufactured by Amneal Pharmaceuticals of New York LLC, is $0.2863 per EA (NDC 00115132510), effective Sep 30, 2026.
How has the price of FENOFIBRIC ACID DR 135 MG CAP changed over time?
Over the history we have for it, the NADAC for FENOFIBRIC ACID DR 135 MG CAP has declined 20.7%. It has been tracked across 92 weekly CMS publications since Jan 1, 2025.
What are the highest and lowest recorded NADAC prices for FENOFIBRIC ACID DR 135 MG CAP?
Since Jan 1, 2025, the NADAC for FENOFIBRIC ACID DR 135 MG CAP has ranged from a low of $0.2366 (Mar 18, 2026) to a high of $0.3612 (Jan 15, 2025), with a median of $0.2796 per EA.
Are there cheaper alternatives to FENOFIBRIC ACID DR 135 MG CAP?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as FENOFIBRIC ACID DR 135 MG CAP in a comparable dosage form, but none are currently priced below it.
Who manufactures FENOFIBRIC ACID DR 135 MG CAP?
FENOFIBRIC ACID DR 135 MG CAP (NDC 00115132510) is labeled by Amneal Pharmaceuticals of New York LLC, and CMS classifies it as a generic product.